Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > QuantuMDx closes $8.42m investment round for prototyping handheld MDx device

Abstract:
Handheld molecular diagnostics device pioneer QuantuMDx Group announced it had closed an $8.42m funding round it syndicated with philanthropist private investors and the University of Newcastle upon Tyne following the recent publicity success of its Indiegogo crowdfunding campaign.

QuantuMDx closes $8.42m investment round for prototyping handheld MDx device

Newcastle, UK | Posted on June 2nd, 2014

The funds will be used to further optimize and trial Q-POC™, QuantuMDx's handheld DNA sequencing & genotyping device, in addition to extending the Company's assay pipeline, expanding its research teams and appointing an Advisory Board.

Elaine Warburton CEO and Co-Founder says "2014 will be an immensely exciting year for QuantuMDx as we demonstrate, in real-time, our ability to undertake 15 minute sample-to-result analysis for complex molecular diagnostics. Later this year when we formally unveil our prototype, we anticipate much interest from Life Science and Pharma companies seeking a low cost, high quality POC platform for diagnostics and to support drug development. Furthermore, we're now looking to appoint a number of high quality, commercially minded but fun people onto our research team and also a number of key opinion leaders onto our Advisory Board."

"Most of the basic research was completed last year and we moved into an engineering phase to integrate these technologies and chemistries at the beginning of this year. We are now moving into the testing phase of our alpha prototype," says Jonathan O'Halloran, CSO, inventor and Co-Founder. "Excitingly, we envisage these devices to be readily distributed globally due to their low cost, fast turn-around times and referral standard testing. With networked devices all over the world we will have a platform to monitor emerging pathogens and drug resistance hotspots in real-time; a concept we like to call the Internet of Life™".

Field trials will commence early 2015 for Q-POC™'s first assays in malaria speciation/drug resistance, in partnership with NGOs and hospitals in several African countries, and a companion diagnostic for warfarin within the UK's National Health Service, in anticipation of a commercial launch later in 2015.

####

About QuantuMDx Group
QuantuMDx Group is one of the most exciting biotechs to emerge from the UK and is developing a low cost, simple-to-use, handheld laboratory for 15-minute diagnosis of disease at the patient’s side, for commercialisation in 2015. The robust device, which reads and sequences DNA and converts it into binary code using a tiny computer chip, is ideally suited to help address the humanitarian health burden by offering molecular diagnostics at a fraction of the price of traditional testing.

Rapidly & accurately detecting and monitoring emerging drug resistance of infectious diseases such as malaria, TB and HIV will enable health professionals to immediately prescribe the most effective drug against that disease. Once the device has passed regulatory approval, it will be available in developed countries for infectious disease testing and rapid cancer profiling and, in time, be available over-the-counter at pharmacies.

Headquartered at The International Centre for Life in Newcastle, UK with subsidiaries in the USA (Chattanooga) and Asia (A*Star’s Genome Institute of Singapore), QuantuMDx was co-founded by Elaine Warburton, inventor and CSO Jonathan O’Halloran and CFO Julian Warburton. Fellow Board members include CMO Professor Sir John Burn, COO Dr Sam Whitehouse and President of QuantuMDx USA Paul Fitzpatrick. Prof Sanjeev Krishna chairs the Infectious Disease Advisory Committee.

QuantuMDx has received numerous awards for innovation and is the recipient of a number of large grants from The UK’s Technology Strategy Board (TB diagnostic), The Biomedical Catalyst Fund (tumour profiler), NHS NIHR’s Invention for Innovation Program (DNA sequencer) and the European Union (“NanoMal” malaria diagnostic).

For more information, please click here

Contacts:
Maggie Love
Business Development and Marketing Executive
QuantuMDx Group Limited
Mob: + 44 (0) 7584 504 327
Office: + 44 (0) 870 803 1234

Copyright © QuantuMDx Group

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Dr Barbara Armbruster promoted to Worldwide Sales and Marketing Director for XEI Scientific September 27th, 2016

Fighting cancer with sticky nanoparticles September 27th, 2016

Gold nanoparticles conjugated quercetin inhibits epithelial-mesenchymal transition, angiogenesis and invasiveness via EGFR/VEGFR-2 mediated pathway in breast cancer September 27th, 2016

UNAM develops successful nano edible coating which increases life food September 27th, 2016

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

Carbodeon Ltd Oy Closes EUR 1.5 million Funding Round From Straightforward Capital: Carbodeon will accelerate its nanodiamonds business and expand manufacturing capacity August 21st, 2016

Leading Advanced Materials Manufacturer Pixelligent Closes $10.4 Million in Funding: Capital Will Boost Capacity for North American Manufacturing, Drive Asian Expansion, and Continue Innovation in Solid State Lighting and OLED Display Applications August 16th, 2016

Harris & Harris Group to Host a Shareholder Update Call, Including a Presentation by One of Its Precision Health and Medicine Portfolio Companies, Muses Labs, Inc., on August 23, 2016 August 16th, 2016

NanoLabNL boosts quality of research facilities as Dutch Toekomstfonds invests firmly June 10th, 2016

Investments/IPO's/Splits

Nanotech Grants Options September 22nd, 2016

Arrowhead Pharmaceuticals to Present at Upcoming September Conferences September 1st, 2016

Industrial Nanotech, Inc. Provides Shareholder Update August 22nd, 2016

Carbodeon Ltd Oy Closes EUR 1.5 million Funding Round From Straightforward Capital: Carbodeon will accelerate its nanodiamonds business and expand manufacturing capacity August 21st, 2016

Nanomedicine

Fighting cancer with sticky nanoparticles September 27th, 2016

Gold nanoparticles conjugated quercetin inhibits epithelial-mesenchymal transition, angiogenesis and invasiveness via EGFR/VEGFR-2 mediated pathway in breast cancer September 27th, 2016

Tattoo therapy could ease chronic disease: Rice-made nanoparticles tested at Baylor College of Medicine may help control autoimmune diseases September 23rd, 2016

BBI Solutions launches innovative conjugate blocking technology that enhances signal intensity for lateral flow immunoassays September 20th, 2016

Announcements

Dr Barbara Armbruster promoted to Worldwide Sales and Marketing Director for XEI Scientific September 27th, 2016

Fighting cancer with sticky nanoparticles September 27th, 2016

Gold nanoparticles conjugated quercetin inhibits epithelial-mesenchymal transition, angiogenesis and invasiveness via EGFR/VEGFR-2 mediated pathway in breast cancer September 27th, 2016

UNAM develops successful nano edible coating which increases life food September 27th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic